Immutep Ltd · ASX:IMM
Immutep — Investor Presentation (January 2020)
33 slides from Immutep's investor presentation, Jan 10, 2020
Slide 1: The global leader in developing LAG-3 therapeutics
For personal use only The global leader in developing LAG-3 therapeutics Corporate Presentation January 2020 (ASX: IMM, NASDAQ: IMMP)
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements For personal use only The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further
Slide 3: Company Snapshot
Company Snapshot For personal use only Financial Snapshot • Global leadership position in LAG-3 IMM (Australian Securities Exchange) Ticker symbols IMMP (NASDAQ) • Four LAG-3 related candidates in immuno-oncology Securities on issue(1) 391.6 million ordinary shares (as at 6 January 2020) and autoimm
Slide 4: Directors & Officers
Directors & Officers For personal use only Russell J. Howard, PhD, Non-Executive Chairman Scientist, executive manager and entrepreneur; previously CEO of Maxygen & Oakbio, positions at NIH, DNAX, Affymax Pete A Meyers, Non-Executive Director & Deputy Chairman Current Chief Financial Officer of Eagl
Slide 5: LAG-3 Overview
For personal use only LAG-3 Overview - the most promising immune checkpoint -
Slide 6: Immune Checkpoint Landscape beyond PD-1 and CTLA-4
Immune Checkpoint Landscape beyond PD-1 and CTLA-4 For personal use only 2015 and 2019 18 16 14 No. of Products 12 10 8 6 4 2 0 (2015) (2019) (2015) (2019) (2015) (2019) (2015) (2019) (2015) (2019) (2015) (2019) CD80 GITR ICOS LAG3 TIGIT TIM3 Preclin Ph I Ph I/II Ph II Ph II/III Ph III Notes: 6 * Mo
Slide 7: LAG-3 as a Therapeutic Target
LAG-3 as a Therapeutic Target For personal use only LAG-3, an immune checkpoint, is widely expressed on tumor infiltrating lymphocytes (TILs) and cytotoxic T cells → Prime target for immune therapy LAG-3 / MHC Class II Interaction → Positive regulation of antigen presenting cells (APCs) → LAG-3 incr
Slide 8: Targeting LAG-3 / MHC II may lead to multiple therapeutics in numerous indications
Targeting LAG-3 / MHC II may lead to multiple therapeutics in numerous indications For personal use only IMMUNOSTIMULATION IMMUNOSUPPRESSION APC Activator Efti Agonistic IMP761 mAb APC LAG-3 Depleting mAb MHCII GSK’781 T Cell Antagonistic Partnered with mAb LAG525 Partnered with LAG-3 T Cell Rheumat
Slide 9: Immutep Controlled Immunotherapy Pipeline
Immutep Controlled Immunotherapy Pipeline* For personal use only Commercial Market Size(5) Program Preclinical Phase I Phase II Late Stage(4) Rights (by) Metastatic Breast Cancer (Chemo – IO) US$12.7 billion AIPAC (2024) Non-Small-Cell Lung Carcinoma (IO – IO) (1) US$33.9 billion TACTI-002 (2026) He
Slide 10: Immutep Out-Licensed Immunotherapy Pipeline
Immutep Out-Licensed Immunotherapy Pipeline* For personal use only Commercial Program Preclinical Phase I Phase II Late Stage(1) Rights/Partners Solid Tumors + Blood Cancer (IO-IO Combo) Triple Negative Breast Cancer (Chemo-IO Combo) Oncology LAG525 Global Rights Melanoma (IO-IO-Small Molecule Combo
Slide 11: Lead Program Eftilagimod Alpha (efti or IMP321)
For personal use only Lead Program Eftilagimod Alpha (efti or IMP321) - APC activation -
Slide 12: Efti: IO Therapy Response Rates
Efti: IO Therapy Response Rates For personal use only Approximately 70-80% of patients do not respond to anti-PD-1 monotherapy(1) How can we enable more efficacious T-cell responses? • immunogenic cell death to liberate/uncover tumor antigens • cross-presentation of those antigens • recruitment of T
Slide 13: Efti: an Innovative LAG-3 IO Product Candidate
Efti: an Innovative LAG-3 IO Product Candidate For personal use only • the only APC targeting LAG-3 product candidate currently in clinical development • a unique approach (“turning cold tumors into hot tumors” with LAG-3) • synergistic with other therapeutic agents and modalities e.g. IO agents or
Slide 14: Efti: a pipeline in a product
Efti: a pipeline in a product For personal use only Trafficking of T cells to Efti has disruptive potential for oncology. tumors (CTLs) ✓ First-in-Class MHCII agonist Priming and activation 4 (APCs & T cells) ✓ good safety profile 3 ✓ encouraging efficacy data Infiltration of T cells 5 into tumors ✓
Slide 15: Efti: a pipeline in a product
Efti: a pipeline in a product For personal use only Efti is the ideal candidate to combine with ✓ chemo and ✓ PD-1/PD-L1 antagonists Chemotherapy Eftilagimod PD-1 / PD-L1 Which kind of combinations Alpha were successful in the past? Pembrolizumab • Different MoA to hit virus/cancer simultanously Tax
Slide 16: Efti Clinical Development: AIPAC (Phase IIb)
Efti Clinical Development AIPAC (Phase IIb) AIPAC: Active Immunotherapy PAClitaxel in HER2-/ HR+ metastatic breast cancer (MBC) For personal use only Arm 1, 113 patients: Phase IIb, Patients with paclitaxel + efti Primary: PFS multinational, HR+/HER2- Secondary: OS, safety, randomized, MBC Arm 2, 11
Slide 17: Treatment Landscape for HR+/HER2- MBC
Treatment Landscape for HR+/HER2- MBC For personal use only Epidemiology: • 812,500 HR+/HER2- diagnoses per annum worldwide(1) • approximately 250,000 develop metastatic disease and are eligible to receive chemotherapy • Despite all changes → no improvement for patients receiving first-line chemothe
Slide 18: Efti Clinical Development: TACTI-mel (Phase I)
Efti Clinical Development TACTI-mel (Phase I) TACTI-mel: Two ACTive Immunotherapeutics in Melanoma For personal use only Recommended Phase I, multicenter, 24 patients, efti (IMP321) + anti- Phase II dose, open label, 4 cohorts of 6 patients PD-1 (Keytruda) safety and dose escalation tolerability St
Slide 19: TACTI-mel: Results (Parts A + B)
Efti Clinical Development TACTI-mel: Results (Parts A + B) For personal use only Swimmerplot Parts A + B (starting cycle 1 day 1 pembrolizumab) Conclusion • No treatment termination due to safety issues with the combination • 9 patients (38%) on treatment for ~12 months → durable responses / disease
Slide 20: Efti Clinical Development: TACTI-002 (Phase II)
Efti Clinical Development TACTI-002 (Phase II) TACTI-002: Two ACTive Immunotherapeutics in different indications For personal use only Up to 109 patients Phase II, multi-national, ORR, PFS, OS, PK, efti (IMP321) + anti-PD- with NSCLC or open label, Simon`s 2 biomarker, safety and 1 (Keytruda) HNSCC
Slide 21: Efti Clinical Development: INSIGHT-004 (Phase I)
Efti Clinical Development INSIGHT-004 (Phase I) INSIGHT-004: dose escalation of efti in combination with avelumab For personal use only Dose escalation, solid efti (IMP321) + avelumab Phase I, RP2D, Safety, ORR, tumors, 2 cohorts of 6 (Bavenico) for 6 months + 6 monocenter DE, PFS, PK, PD patients
Slide 22: Eftilagimod Alpha Partnerships
Eftilagimod Alpha Partnerships For personal use only • EOC, an Eddingpharm spin-off holding the Chinese rights for efti, Phase I study in MBC ongoing • Milestone and royalty bearing partnership • Spin off from NEC, Japan. Est. December 2016; aims to develop cancer drugs discovered by artificial inte
Slide 23: Out-Licensed Immunotherapy Pipeline
For personal use only Out-Licensed Immunotherapy Pipeline
Slide 24: LAG525 (IMP701) for Cancer
LAG525 (IMP701) for Cancer For personal use only • Novartis holds an exclusive WW licence to develop and commercialise LAG525 (which is derived from Immutep’s antagonist antibody known as IMP701) • 1st and 2nd milestone payments received by Immutep in August 2015 (undisclosed) and August 2017 (US$1
Slide 25: GSK'781 (IMP731) for Autoimmune Diseases
GSK’781 (IMP731) for Autoimmune Diseases For personal use only • GSK holds an exclusive WW licence to develop and commercialise GSK’781 (which is derived from Immutep’s depleting antibody known as IMP731) • Up to ₤64 million in upfront payments and milestones, plus royalties • GSK portfolio review i
Slide 26: IMP761 (Autoimmune Diseases)
For personal use only IMP761 (Autoimmune Diseases)
Slide 27: Broad potential in targeting auto-reactive memory T cells with IMP761
Broad potential in targeting auto-reactive memory T cells with IMP761 For personal use only THE PRESENT: FIGHTING THE SYMPTOMS Treating general inflammation: corticoids, methotrexate, anti-TNF-α, -IL-6, -IL-17, -IL-23 mAbs THE FUTURE: FIGHTING THE CAUSE Treating the disease process: silencing the fe
Slide 28: IMP761 Overview
IMP761 Overview For personal use only • The Concept: treating the cause of autoimmune diseases, not just the symptoms • The Target: the self-peptide specific memory T cells harboring LAG-3 • The Tool: an agonistic LAG-3-specific mAb down-modulating self-peptide-induced TCR signaling • The Evidence (
Slide 29: LAG-3 Landscape and Outlook
For personal use only LAG-3 Landscape and Outlook
Slide 30: LAG-3 Therapeutic Landscape Overview
LAG-3 Therapeutic Landscape Overview For personal use only Company Program Preclinical Phase I Phase II Phase III Total Trials Patients on Trials Agonist Eftilagimod Alpha Eftilagimod Alpha 2 3 22 4244 424 BMS Relatlimab 6 19 2 27 9,422 Novartis LAG525 (IMP701) 1 4 1,122 LAG525 (IMP701) 1 4 5 1,100
Slide 31: 2020 Clinical Guidance
2020 Clinical Guidance* For personal use only Reported 2019: Upcoming Data 2020 (est): ✓ TACTI-002 to commence, Phase II trial in • MBC - mature, robust PFS & ORR data from AIPAC: Q1 collaboration with MSD: H1 2019 2020 (March) • NSCLC 1st line - more data from Stages 1 and 2 from TACTI- ✓ IMP761 pr
Slide 32: Highlights
Highlights For personal use only Global Leader in • More clinical-stage LAG-3 programs than any other company Development of LAG-3 • Dr. Frédéric Triebel, MD Ph.D., Immutep’s Chief Scientific Officer and Chief Therapeutics Medical Officer, discovered the LAG-3 gene First-in-Class / • LAG-3 fusion pr
Slide 33: Thank you!
For personal use only Thank you!